title: Oculohypotensive effect of angiotensin-converting enzyme inhibitors in acute and chronic models of glaucoma.
abstract: We have studied the effects of various angiotensin-converting enzyme (ACE) inhibitors on intraocular pressure (IOP) of rabbits with experimentally induced ocular hypertension and their mechanism of action. Acute ocular hypertension was induced by infusion of 5% glucose (15 ml/kg) through marginal ear vein, whereas chronic glaucoma was induced by injection of alpha-chymotrypsin into the posterior chamber of the eye. IOP was measured by tonometer. All ACE inhibitors were instilled topically in the eye in a sterile solution. The effect of ACE inhibitors also was studied on serum cholinesterase (true and pseudo) and the enzyme ACE in vitro. Enalaprilat, ramiprilat, and fosinopril produced a time-dependent decrease of IOP in both acute and chronic models of ocular hypertension in rabbits. The decrease in IOP was observed for >4 h, and the extent of decrease was comparable to that with both pilocarpine and betaxolol. Prodrugs enalapril and ramipril failed to produced any change in IOP. Losartan also produced a significant decrease in IOP in the chronic model of ocular hypertension in rabbits. All the three ACE inhibitors were found to inhibit ACE activity in aqueous humor. The enzyme cholinesterase was found to be inhibited by enalaprilat, ramiprilat, and fosinopril. However, atropine did not alter the IOP-lowering effect of enalaprilat in rabbits. Indomethacin pretreatment produced slight but significant inhibition of the IOP-lowering effect of enalaprilat in rabbits. Our data suggest that ACE inhibitors enalaprilat, ramiprilat, and fosinopril produce a significant ocular hypotensive effect in acute and chronic models of ocular hypertension in rabbits. Inhibition of ACE in aqueous humor, and in ocular tissues, resulting in reduced angiotensin II formation, could be one of the major mechanisms responsible for the IOP reduction by ACE inhibitors in rabbits.
authors.affiliation: Department of Pharmacology, L.M. College of Pharmacy, Navarangpura, Ahmedabad, India.
authors.forename: G B
authors.initials: GB
authors.lastname: Shah
authors.forename: S
authors.initials: S
authors.lastname: Sharma
authors.forename: A A
authors.initials: AA
authors.lastname: Mehta
authors.forename: R K
authors.initials: RK
authors.lastname: Goyal
mesh_terms: D000208:Acute Disease; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000818:Animals; D001082:Aqueous Humor / Q000201:enzymology; D002802:Cholinesterases / Q000378:metabolism; D002908:Chronic Disease; D002918:Chymotrypsin / Q000494:pharmacology; D005901:Glaucoma / Q000188:drug therapy* / Q000503:physiopathology; D007429:Intraocular Pressure / Q000187:drug effects*; D009798:Ocular Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D007703:Peptidyl-Dipeptidase A / Q000097:blood / Q000378:metabolism; D011817:Rabbits
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D002802:Cholinesterases; D007703:Peptidyl-Dipeptidase A; D002918:Chymotrypsin